Literature DB >> 23824824

Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.

Per Johan Klasse1, Rafael S Depetris, Robert Pejchal, Jean-Philippe Julien, Reza Khayat, Jeong Hyun Lee, Andre J Marozsan, Albert Cupo, Nicolette Cocco, Jacob Korzun, Anila Yasmeen, Andrew B Ward, Ian A Wilson, Rogier W Sanders, John P Moore.   

Abstract

We describe methods to improve the properties of soluble, cleaved gp140 trimers of the human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (Env) for use in structural studies and as immunogens. In the absence of nonionic detergents, gp140 of the KNH1144 genotype, terminating at residue 681 in gp41 (SOSIP.681), has a tendency to form higher-order complexes or aggregates, which is particularly undesirable for structure-based research. We found that this aggregation in the absence of detergent does not involve the V1, V2, or V3 variable regions of gp120. Moreover, we observed that detergent forms micelles around the membrane-proximal external region (MPER) of the SOSIP.681 gp140 trimers, whereas deletion of most of the MPER residues by terminating the gp140 at residue 664 (SOSIP.664) prevented the aggregation that otherwise occurs in SOSIP.681 in the absence of detergent. Although the MPER can contribute to trimer formation, truncation of most of it only modestly reduced trimerization and lacked global adverse effects on antigenicity. Thus, the MPER deletion minimally influenced the kinetics of the binding of soluble CD4 and a CD4-binding site antibody to immobilized trimers, as detected by surface plasmon resonance. Furthermore, the MPER deletion did not alter the overall three-dimensional structure of the trimers, as viewed by negative-stain electron microscopy. Homogeneous and aggregate-free MPER-truncated SOSIP Env trimers are therefore useful for immunogenicity and structural studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23824824      PMCID: PMC3754145          DOI: 10.1128/JVI.01226-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  An alternative conformation of the gp41 heptad repeat 1 region coiled coil exists in the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor.

Authors:  Claudia C Mische; Wen Yuan; Bettina Strack; Stewart Craig; Michael Farzan; Joseph Sodroski
Journal:  Virology       Date:  2005-07-20       Impact factor: 3.616

2.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

Authors:  T Muster; R Guinea; A Trkola; M Purtscher; A Klima; F Steindl; P Palese; H Katinger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

3.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

Authors:  Emilia Falkowska; Alejandra Ramos; Yu Feng; Tongqing Zhou; Stephanie Moquin; Laura M Walker; Xueling Wu; Michael S Seaman; Terri Wrin; Peter D Kwong; Richard T Wyatt; John R Mascola; Pascal Poignard; Dennis R Burton
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Authors:  Simon Beddows; Michael Franti; Antu K Dey; Marc Kirschner; Sai Prasad N Iyer; Danielle C Fisch; Thomas Ketas; Eloisa Yuste; Ronald C Desrosiers; Per Johan Klasse; Paul J Maddon; William C Olson; John P Moore
Journal:  Virology       Date:  2006-11-28       Impact factor: 3.616

6.  Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.

Authors:  Antu K Dey; Kathryn B David; Per J Klasse; John P Moore
Journal:  Virology       Date:  2006-11-07       Impact factor: 3.616

7.  Molecular architecture of native HIV-1 gp120 trimers.

Authors:  Jun Liu; Alberto Bartesaghi; Mario J Borgnia; Guillermo Sapiro; Sriram Subramaniam
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

8.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

Authors:  Zhen-Yu J Sun; Kyoung Joon Oh; Mikyung Kim; Jessica Yu; Vladimir Brusic; Likai Song; Zhisong Qiao; Jia-huai Wang; Gerhard Wagner; Ellis L Reinherz
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

9.  Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.

Authors:  Gilad Ofek; Min Tang; Anna Sambor; Hermann Katinger; John R Mascola; Richard Wyatt; Peter D Kwong
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans.

Authors:  Jean-Philippe Julien; Devin Sok; Reza Khayat; Jeong Hyun Lee; Katie J Doores; Laura M Walker; Alejandra Ramos; Devan C Diwanji; Robert Pejchal; Albert Cupo; Umesh Katpally; Rafael S Depetris; Robyn L Stanfield; Ryan McBride; Andre J Marozsan; James C Paulson; Rogier W Sanders; John P Moore; Dennis R Burton; Pascal Poignard; Andrew B Ward; Ian A Wilson
Journal:  PLoS Pathog       Date:  2013-05-02       Impact factor: 6.823

View more
  59 in total

1.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Anila Yasmeen; Gabriel Ozorowski; Eden P Go; Laura K Pritchard; Miklos Guttman; Thomas A Ketas; Christopher A Cottrell; Ian A Wilson; Rogier W Sanders; Albert Cupo; Max Crispin; Kelly K Lee; Heather Desaire; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

2.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

Authors:  Steven W de Taeye; Gabriel Ozorowski; Alba Torrents de la Peña; Miklos Guttman; Jean-Philippe Julien; Tom L G M van den Kerkhof; Judith A Burger; Laura K Pritchard; Pavel Pugach; Anila Yasmeen; Jordan Crampton; Joyce Hu; Ilja Bontjer; Jonathan L Torres; Heather Arendt; Joanne DeStefano; Wayne C Koff; Hanneke Schuitemaker; Dirk Eggink; Ben Berkhout; Hansi Dean; Celia LaBranche; Shane Crotty; Max Crispin; David C Montefiori; P J Klasse; Kelly K Lee; John P Moore; Ian A Wilson; Andrew B Ward; Rogier W Sanders
Journal:  Cell       Date:  2015-12-17       Impact factor: 41.582

3.  Crystal structure of a soluble cleaved HIV-1 envelope trimer.

Authors:  Jean-Philippe Julien; Albert Cupo; Devin Sok; Robyn L Stanfield; Dmitry Lyumkis; Marc C Deller; Per-Johan Klasse; Dennis R Burton; Rogier W Sanders; John P Moore; Andrew B Ward; Ian A Wilson
Journal:  Science       Date:  2013-10-31       Impact factor: 47.728

4.  Computational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State.

Authors:  Muhibur Rasheed; Radhakrishna Bettadapura; Chandrajit Bajaj
Journal:  Structure       Date:  2015-06-02       Impact factor: 5.006

5.  Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Authors:  Lindsay Wieczorek; Shelly J Krebs; Vaniambadi Kalyanaraman; Stephen Whitney; Sodsai Tovanabutra; Carlos G Moscoso; Eric Sanders-Buell; Constance Williams; Bonnie Slike; Sebastian Molnar; Vincent Dussupt; S Munir Alam; Agnes-Laurence Chenine; Tina Tong; Edgar L Hill; Hua-Xin Liao; Michael Hoelscher; Leonard Maboko; Susan Zolla-Pazner; Barton F Haynes; Michael Pensiero; Francine McCutchan; Shawyon Malek-Salehi; R Holland Cheng; Merlin L Robb; Thomas VanCott; Nelson L Michael; Mary A Marovich; Carl R Alving; Gary R Matyas; Mangala Rao; Victoria R Polonis
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

6.  Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function.

Authors:  Hanh T Nguyen; Nirmin Alsahafi; Andrés Finzi; Joseph G Sodroski
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

7.  The immune space: a concept and template for rationalizing vaccine development.

Authors:  Amapola Manrique; Elizabeth Adams; Dan H Barouch; Pat Fast; Barney S Graham; Jerome H Kim; James G Kublin; Margaret McCluskey; Giuseppe Pantaleo; Harriet L Robinson; Nina Russell; William Snow; Margaret I Johnston
Journal:  AIDS Res Hum Retroviruses       Date:  2014-06-26       Impact factor: 2.205

8.  A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.

Authors:  Pavel Pugach; Gabriel Ozorowski; Albert Cupo; Rajesh Ringe; Anila Yasmeen; Natalia de Val; Ronald Derking; Helen J Kim; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Jean-Philippe Julien; Dennis R Burton; Ian A Wilson; Rogier W Sanders; P J Klasse; Andrew B Ward; John P Moore
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

9.  Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of Virions.

Authors:  Ellen White; Fan Wu; Elena Chertova; Julian Bess; James D Roser; Jeffrey D Lifson; Vanessa M Hirsch
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

10.  HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike.

Authors:  Dirk Eggink; Steven W de Taeye; Ilja Bontjer; Per Johan Klasse; Johannes P M Langedijk; Ben Berkhout; Rogier W Sanders
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.